The clinical significance of GluN2B is reinforced by a multisite postmortem study showing that lower cortical gene expression of GluN2B correlates with better cognitive performance in people diagnosed with prodromal AD [119]. The gene discussed is GRIN2B; the disease is Alzheimer disease.